The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease

被引:15
作者
Bornfeldt, Karin E. [1 ,2 ]
机构
[1] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[2] Univ Washington, Dept Lab Med & Pathol, Med Diabet Inst, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
atherosclerosis; biomarkers; humans; hyperglycemia; lipoproteins; TRIGLYCERIDE-RICH LIPOPROTEINS; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN C-III; CHOLESTEROL-FED RABBITS; ATHEROSCLEROTIC LESIONS; INSULIN-RESISTANCE; MACROPHAGE PHENOTYPE; ELEVATED GLUCOSE; GENE-EXPRESSION; LIPASE ACTIVITY;
D O I
10.1161/ATVBAHA.122.317163
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both type 1 and type 2 diabetes are associated with an increased risk of atherosclerotic cardiovascular disease (CVD). Research based on human-first or bedside-to-bench approaches has provided new insights into likely mechanisms behind this increased risk. Although both forms of diabetes are associated with hyperglycemia, it is becoming increasingly clear that altered lipoprotein metabolism also plays a critical role in predicting CVD risk in people with diabetes. This review examines recent findings indicating that increased levels of circulating remnant lipoproteins could be a missing link between diabetes and CVD. Although CVD risk associated with diabetes is clearly multifactorial in nature, these findings suggest that we should increase efforts in evaluating whether remnant lipoproteins or the proteins that govern their metabolism are biomarkers of incident CVD in people living with diabetes and whether reducing remnant lipoproteins will prevent the increased CVD risk associated with diabetes.
引用
收藏
页码:819 / 830
页数:12
相关论文
共 116 条
[1]   SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice [J].
Al-Sharea, Annas ;
Murphy, Andrew J. ;
Huggins, L. A. ;
Hu, Y. ;
Goldberg, Ira J. ;
Nagareddy, Prabhakara R. .
ATHEROSCLEROSIS, 2018, 271 :166-176
[2]   N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels [J].
Alexander, Veronica J. ;
Xia, Shuting ;
Hurh, Eunju ;
Hughes, Steven G. ;
O'Dea, Louis ;
Geary, Richard S. ;
Witztum, Joseph L. ;
Tsimikas, Sotirios .
EUROPEAN HEART JOURNAL, 2019, 40 (33) :2785-2796
[3]   Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].
Anker, Stefan D. ;
Butler, Javed ;
Filippatos, Gerasimos ;
Ferreira, Joao P. ;
Bocchi, Edimar ;
Boehm, Michael ;
Brunner-La Rocca, Hans-Peter ;
Choi, Dong-Ju ;
Chopra, Vijay ;
Chuquiure-Valenzuela, Eduardo ;
Giannetti, Nadia ;
Gomez-Mesa, Juan Esteban ;
Janssens, Stefan ;
Januzzi, James L. ;
Gonzalez-Juanatey, Jose R. ;
Merkely, Bela ;
Nicholls, Stephen J. ;
Perrone, Sergio V. ;
Pina, Ileana L. ;
Ponikowski, Piotr ;
Senni, Michele ;
Sim, David ;
Spinar, Jindrich ;
Squire, Iain ;
Taddei, Stefano ;
Tsutsui, Hiroyuki ;
Verma, Subodh ;
Vinereanu, Dragos ;
Zhang, Jian ;
Carson, Peter ;
Lam, Carolyn Su Ping ;
Marx, Nikolaus ;
Zeller, Cordula ;
Sattar, Naveed ;
Jamal, Waheed ;
Schnaidt, Sven ;
Schnee, Janet M. ;
Brueckmann, Martina ;
Pocock, Stuart J. ;
Zannad, Faiez ;
Packer, Milton .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461
[4]   Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D [J].
Basu, Arpita ;
Bebu, Ionut ;
Jenkins, Alicia J. ;
Stoner, Julie A. ;
Mang, Ying ;
Klein, Richard L. ;
Lopes-Virella, Maria F. ;
Garvey, W. Timothy ;
Budoff, Matthew J. ;
Alaupovic, Petar ;
Lyons, Timothy J. .
JOURNAL OF LIPID RESEARCH, 2019, 60 (08) :1432-1439
[5]   Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models [J].
Basu, Debapriya ;
Bornfeldt, Karin E. .
FRONTIERS IN ENDOCRINOLOGY, 2020, 11
[6]   Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition [J].
Basu, Debapriya ;
Huggins, Lesley-Ann ;
Scerbo, Diego ;
Obunike, Joseph ;
Mullick, Adam E. ;
Rothenberg, Paul L. ;
Di Prospero, Nicholas A. ;
Eckel, Robert H. ;
Goldberg, Ira J. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (09) :2207-2216
[7]   Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis [J].
Baumgartl, J ;
Baudler, S ;
Scherner, M ;
Babaev, V ;
Makowski, L ;
Suttles, J ;
McDuffie, M ;
Fazio, S ;
Kahn, CR ;
Hotamisligil, GS ;
Krone, W ;
Linton, M ;
Brüning, JC .
CELL METABOLISM, 2006, 3 (04) :247-256
[8]   Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study [J].
Bebu, Ionut ;
Braffett, Barbara H. ;
Orchard, Trevor J. ;
Lorenzi, Gayle M. ;
Lachin, John M. .
DIABETES CARE, 2019, 42 (07) :1284-1289
[9]   Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis [J].
Biddinger, Sudha B. ;
Hernandez-Ono, Antonio ;
Rask-Madsen, Christian ;
Haas, Joel T. ;
Aleman, Jose O. ;
Suzuki, Ryo ;
Scapa, Erez F. ;
Agarwal, Chhavi ;
Carey, Martin C. ;
Stephanopoulos, Gregory ;
Cohen, David E. ;
King, George L. ;
Ginsberg, Henry N. ;
Kahn, C. Ronald .
CELL METABOLISM, 2008, 7 (02) :125-134
[10]   Intestine-specific expression of Apobec-1 rescues apolipoprotein B RNA editing and alters chylomicron production in Apobec1-/- mice [J].
Blanc, Valerie ;
Xie, Yan ;
Luo, Jianyang ;
Kennedy, Susan ;
Davidson, Nicholas O. .
JOURNAL OF LIPID RESEARCH, 2012, 53 (12) :2643-2655